Alkem launches breast cancer treatment drug palbociclib (Palbo) in India

Alkem Oncology has recently launched its breast cancer drug, palbociclib under the brand name, Palbo. It comes in capsule form in multiple dose strengths with varied pricing ranges, including 125 mg at Rs 6,125/- for 21 capsules, 100mg at Rs 6,062/- and 75 mg at Rs 6,000/- for 21 capsules, a company statement notified.

According to the statement, palbociclib is an endocrine-based chemotherapeutic agent used in combination with other anti-neoplastic agents to treat HER2-negative and HR-positive advanced or metastatic breast cancer which helps in inhibiting cancer cell growth.

Palbociclib, along with AI and SERD (fulvestrant) has been shown to significantly improve longevity among breast cancer patients, slow down the progression of disease and reduce cancer-related symptoms. The capsules are taken orally with food, in combination with an aromatase inhibitor or fulvestrant, the statement concluded.